Test Center

My Recent Searches

  • No Recent Search.

My Tests Viewed

  • No Test Viewed.
Test Name

ABL Kinase Domain Mutation in CML, Cell-based

CPT Code(s)

81170

Methodology

Nested Polymerase Chain Reaction • Real-Time Polymerase Chain Reaction (RT-PCR) • Sequencing

Reference Range(s)

See Laboratory Report

Clinical Significance

Imatinib mesylate (ST1571;Gleevec) is a selective BCR-ABL kinase inhibitor, effective in the treatment of chronic myelogenous leukemia (CML). Most patients in chronic phase maintain durable responses; however, many in blast crisis fail to respond, or relapse quickly. ABL kinase domain mutations are the most commonly identified mechanism associated with relapse. The molecular monitoring in the first few months of therapy may play a crucial role in detecting patients at high risk of Imatinib resistance. This ABL kinase mutation assay may detect drug-resistant mutations before clinical relapse and identify candidate suitable for alternative therapy.

Test FAQ

ABL Kinase Domain Mutation in CML, Cell-based

To view specimen requirements and codes please Select a regional laboratory.

Not sure which laboratory serves your office? Call us 866-MYQUEST (866-697-8378)

Reference ranges are provided as general guidance only. To interpret test results use the reference range in the laboratory report.

The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

* The tests listed by specialist are a select group of tests offered. For a complete list of Quest Diagnostics tests, please refer to our Directory of Services.

16029
16029
16029
16029
16029
16029X
16029
16029
16029
16029
16029X
16029
16029
16029X
16029
16029
16029
16029X
16029
16029
ABL Kinase Domain Mutation in CML, Cell-based
16029